{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:40:23Z","timestamp":1789166423644,"version":"build-2803163510"},"reference-count":49,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Maarten van der Weijden foundation"},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF #11809"],"award-info":[{"award-number":["KWF #11809"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM #19027"],"award-info":[{"award-number":["LSHM #19027"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KWF\/SU2C-DCS International Translational Cancer Research Dream Team Grant","award":["SU2C-AACR-DT1415"],"award-info":[{"award-number":["SU2C-AACR-DT1415"]}]},{"name":"Sacha Swarttouw-Hijmans foundation"},{"DOI":"10.13039\/100004436","name":"Commonwealth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA121113 and CA233259"],"award-info":[{"award-number":["CA121113 and CA233259"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>All stage III colon cancer (CC) patients are recommended adjuvant chemotherapy (ACT) after surgery, while over half are already cured by surgery alone. The prognostic biomarker circulating tumor DNA (ctDNA) could potentially guide the decision on whom to withhold ACT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We assessed the cost-effectiveness of ctDNA-guided ACT de-escalation in stage III CC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A decision model \u201cPATTERN-stageIII\u201d simulates CC from diagnosis till death in surgically treated stage III patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We evaluated administering ACT in all patients (i.e., All ACT strategy), and three ACT de-escalation strategies by omitting ACT in patients who are (Strategy 1) both pT1-3N1 and ctDNA-negative, (Strategy 2) pT1-3N1, have no vascular invasion, and are ctDNA-negative, and (Strategy 3) pT1-2N1 and ctDNA-negative. For each strategy, costs, quality-adjusted life years (QALYs), and net monetary benefit were estimated. Sensitivity analyses assessed changes in ACT effectiveness and ctDNA-related parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In de-escalation strategies 1, 2, and 3, respectively, 52%, 61%, and 88% of patients were predicted to receive ACT, thereby losing 0.322, 0.237, and 0.034 QALYs per person. The \u201cAll ACT strategy\u201d was preferred in terms of cost-effectiveness. Sensitivity analyses demonstrated scenarios where ctDNA-guided de-escalation strategies were cost-effective compared to \u201cAll ACT,\u201d including improved ACT treatment effect in ctDNA-positive patients, higher ctDNA positivity rates, enhanced ctDNA prognostic value, and\/or reduced ctDNA testing costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ctDNA-guided strategies for ACT de-escalation are currently not cost-effective compared to an \u201cAll ACT strategy.\u201d One explanation is the non-negligible recurrence risk in ctDNA-negative patients. ctDNA-guided strategies could potentially become cost-effective if more than two ctDNA-related parameters improve simultaneously.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251384238","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:27:50Z","timestamp":1762428470000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-8063","authenticated-orcid":false,"given":"Haoyue","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Methodology Program, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2201-5794","authenticated-orcid":false,"given":"Astrid","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Methodology Program, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-3382","authenticated-orcid":false,"given":"Marjolein J. E.","family":"Greuter","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Methodology Program, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rubio-Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-1826","authenticated-orcid":false,"given":"Birgit","family":"Lissenberg-Witte","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Methodology Program, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-3130","authenticated-orcid":false,"given":"Gerrit A.","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0214","authenticated-orcid":false,"given":"Niels F. M.","family":"Kok","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-9811","authenticated-orcid":false,"given":"Daan","family":"van den Broek","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-9660","authenticated-orcid":false,"given":"Geraldine R.","family":"Vink","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"},{"name":"Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine M. L.","family":"Roodhart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-5269","authenticated-orcid":false,"given":"Mark","family":"Sausen","sequence":"additional","affiliation":[{"name":"Labcorp, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-5521","authenticated-orcid":false,"given":"Remond J. A.","family":"Fijneman","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-9791","authenticated-orcid":false,"given":"Veerle M. H.","family":"Coup\u00e9","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Methodology Program, De Boelelaan 1117, Postbus 7057, 1007 MB Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.07.031"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092679"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0018"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02017-9"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02115-4"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3616"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6219"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114159"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14926"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102735"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01047-0"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241266164"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-020-01199-4"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0512"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-6559"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1189094"},{"key":"e_1_3_4_20_2","unstructured":"Labcorp Oncology. Labcorp\u00ae Plasma Detect\u2122: a WGS-based ctDNA assay for tumor-informed detection of MRD https:\/\/oncology.labcorp.com\/biopharma-partners\/plasma-detect (2024 accessed 17 July 2024)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32629"},{"key":"e_1_3_4_22_2","unstructured":"Federatie Medisch Specialisten. Adjuvante Systemische Therapie CC. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/colorectaal_carcinoom_crc\/primaire_behandeling_coloncarcinoom_bij_crc\/adjuvante_systemische_therapie_coloncarcinoom_bij_crc.html (2019 accessed 1 May 2024)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33472"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30093-7"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0319-z"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.01.003"},{"key":"e_1_3_4_27_2","unstructured":"Dutch Healthcare Institute. Available from: https:\/\/www.medicijnkosten.nl\/ (2023 accessed 1 May 2024)."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6771"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12470755"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709"},{"key":"e_1_3_4_31_2","first-page":"120","article-title":"Kostenhandleiding: methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg","author":"Hakkaart-van Roijen L","year":"2016","unstructured":"Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, et al. Kostenhandleiding: methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Diemen, 2016, p. 120.","journal-title":"Diemen"},{"key":"e_1_3_4_32_2","article-title":"Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program","volume":"5","author":"Vleugels JL","year":"2017","unstructured":"Vleugels JL, Greuter MJ, Hazewinkel Y, et al. Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program. Endosc Int Open 2017; 5: E1197\u2013E1207.","journal-title":"Endosc Int Open"},{"key":"e_1_3_4_33_2","unstructured":"NZa. Tarieventabel dbc-zorgproducten en overige zorgproducten. Available from: www.puc.overheid.nl\/nza (2023 accessed 1 May 2024)."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-011-0325-z"},{"key":"e_1_3_4_35_2","volume-title":"Verrichtingencodes voor de moleculaire diagnostiek in de pathologie","author":"Pathologie CBNeeM","unstructured":"Pathologie CBNeeM. Verrichtingencodes voor de moleculaire diagnostiek in de pathologie. Nederlandse Vereniging voor Pathologie."},{"key":"e_1_3_4_36_2","volume-title":"Guideline for economic evaluations in healthcare","author":"de Wit A","year":"2024","unstructured":"de Wit A. Guideline for economic evaluations in healthcare 2024. Zorginstituut Nederland."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw404"},{"key":"e_1_3_4_38_2","volume-title":"EQ-5D value sets: inventory, comparative review and user guide","author":"Oppe M","year":"2007","unstructured":"Oppe M, Devlin NJ, Szende A. EQ-5D value sets: inventory, comparative review and user guide. Dordrecht, The Netherlands: Springer, 2007."},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17i1.436"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.198"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01157.x"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0078"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.04.004"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.9"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5098"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.6"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.026"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.10.004"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34149"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251384238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251384238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251384238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:29Z","timestamp":1777588409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251384238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"alternative-id":["10.1177\/17588359251384238"],"URL":"https:\/\/doi.org\/10.1177\/17588359251384238","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251384238"}}